Having trouble viewing this email? View in your browser.

14 June 2016

Dear colleagues,

ESCMID’s viral hepatitis study group ESGVH published a review on recent late-stage clinical trials assessing direct-acting antivirals to treat hepatitis C and highlighting the different available regimens and their success rates.

The Royal Society published an interesting report about European Union’s research funding in the United Kingdom. The society’s goal was to gather evidence about the impact on the research landscape of the 23 June 2016 referendum on the UK’s EU membership.

Best regards, your ESCMID communications editors


ECCMID 2017 Programme Committee selects sessions

The committee met in Vienna last week to set the scientific programme for ECCMID 2017. They selected the 100 top-ranked of the 400 session proposals on topics such as antimicrobial resistance, refugee health, infection control strategies, novel diagnostic approaches and many more. Abstracts may be submitted from 29 August 2016 until 26 January 2017. You may sign up to receive information about abstract submission and approaching deadlines for ECCMID 2017.

› Read more

CMI highlight: Antibiotic de-escalation in bacteraemia, sepsis, VAP

Researchers from the Israel Institute of Technology Technion in Haifa, Israel, conducted a systematic review and meta-analysis to assess the safety and effectiveness of antibiotic de-escalation as part of antibiotic stewardship programmes. They included randomized controlled trials and observational studies comparing antibiotic de-escalation versus no de-escalation in adults with bacteraemia, microbiologically documented pneumonia or severe sepsis. Observational studies suggest that antibiotic susceptibility testing-based de-escalation lowers mortality in bacteraemia, severe sepsis and ventilator-associated pneumonia, the researchers conclude.

› Read more

Programme for ESCMID-ASM conference on drug development online

The programme for the ESCMID-ASM conference on Drug Development to Meet the Challenge of Antimicrobial Resistance in Vienna, Austria, from 21 - 23 September 2016, is online now. Registration will open on 20 June. ESCMID, ASM, EMA, FDA and industry representatives have contributed to designing the programme, which aims to outline problems and discuss solutions to help accelerate the development of new antimicrobials.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.